NCT06963697 — Jaime Leandro Foundation for Therapeutic… neoantigen vaccine trial
Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors
Registry record
| Registry ID | NCT06963697 ↗ |
|---|---|
| Lead sponsor | Jaime Leandro Foundation for Therapeutic Cancer Vaccines |
| Collaborators | — |
| Phase | — |
| Status | Available |
| Indication | Cancer |
| Enrollment | — |
| Start date | — |
| Primary completion | — |
| Last registry update | 15 Jan 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT06963697), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT06963697?
NCT06963697 (Expanded Access To Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors) is registered on ClinicalTrials.gov as having no assigned phase, sponsored by Jaime Leandro Foundation for Therapeutic Cancer Vaccines.
Is NCT06963697 recruiting?
As of the 2026-01-15 registry update, NCT06963697 is listed as "Available". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT06963697?
The lead sponsor is Jaime Leandro Foundation for Therapeutic Cancer Vaccines.
What condition does NCT06963697 study?
The registered condition is Cancer. Primary completion is listed as not listed.
Are results available for NCT06963697?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT06963697.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.